Quartesian Adds Pharmacovigilance to Expand Clinical Data Analysis CapabilitiesHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Quartesian Adds Pharmacovigilance to Expand Clinical Data Analysis CapabilitiesPR NewswireJanuary 7, 2020ReblogShareTweetSharePRINCETON, N.J., Jan. 7, 2020 /PRNewswire/ -- Quartesian, a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the availability of its suite of clinical trial data pharmacovigilance services. The pharmacovigilance market size was valued at USD 3.9 billion in 2017 and is expected to see growth of around 10.7% CAGR from 2018 to 2024 according to a 2019 report from Global Market Insights, Inc.Quartesian Logo 2020MoreQuartesian's services for clinical research now include medical expertise throughout trial design and execution, enhancing their data-driven approach to clinical development. With the addition of pharmacovigilance and related medical monitoring services, Quartesian offers Sponsors deeper skills across a broad spectrum of diseases and technologies. The Quartesian pharmacovigilance team's experience with Oracle Argus, ARISg, AB Cube, RSS, and SCEPTRE safety databases complements Quartesian certifications for multiple EDC systems, including Medrio, Medidata Rave, iMedNet and others.Quartesian's new pharmacovigilance offerings include Safety Management Planning, Case Management, SAE Reconciliation, Literature Case Reporting and more. Quartesian's flexibility to work in either FSP (using the client's safety database) or non FSP models eliminates the pain associated with switching to a new safety system common with other providers while delivering top results in terms of regulatory compliance, productivity and quality. "We are excited to welcome new clients to Quartesian," said Ben Jackson, President and CEO. "Our dedicated team of experienced pharmacovigilance professionals consists of doctors and health care professionals with broad industry experience, delivered at the competitive market rates we are known for. Our ability to supply complete medical data management – from Pharmacovigilance, to Data Management, to Data Visualization Technology under one umbrella will help sponsors with expertise as well as automation."Learn more: For more on Quartesian Pharmacovigilance, visit https://quartesian.com/services/pharmacovigilance/.About QuartesianQuartesian was formed in 2003 to provide customized, insightful data to organizations performing clinical studies. Deep technical expertise pairs with industry experience to provide clinical data services — quickly, efficiently, and at a competitive cost — no matter the size of your business or the phase of your study. At Quartesian, our specialized services teams deliver expertise, innovation, and efficiency for projects across the world. And our reputation for excellence precedes us — we've never issued a change order due to an error in estimated cost. Learn more at www.quartesian.com.  Media Contact: Stephen BoccardoSr. VP Business Development and Commercial Strategy609.454.3312 ext 113stephen.boccardo@quartesian.comCisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/quartesian-adds-pharmacovigilance-to-expand-clinical-data-analysis-capabilities-300982738.htmlSOURCE QuartesianReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoAsian markets continue to slump, as Nikkei enters correction territoryMarketWatch'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoOil’s Worst Week Since 2011 Puts Pressure on OPEC+ to RespondBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchThis company is revamping presentation softwareYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance